Associated Papers
Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.
Meißner T et al.
Cold Spring Harbor Molecular Case Studies, 2017
Select a paper to view details